Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2023/01/049177
CTRI/2023/01/049177
Not yet recruiting
Phase 4

Effectiveness of recombinant human epidermal growth factor (rhEGF) in healing of palatal donor sites post soft tissue graft harvesting - A double blinded parallel arm clinical trial (EGFTRIAL)

OFFICE OF DGDS0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
OFFICE OF DGDS
Status
Not yet recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
OFFICE OF DGDS

Eligibility Criteria

Inclusion Criteria

  • •Patients undergoing palatal soft tissue graft harvesting procedure for various indications as required

Exclusion Criteria

  • •Other than ASA \- 1 Physical status
  • •Known allergy to methyl parapen / propyl paraben
  • •Expecting / Planned / Pregnant women
  • •Lactating mothers
  • •Unwilling for follow ups

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 3
The efficacy of topical recombinant human epidermal growth factor gel in combination with fractional radiofrequency microneedle in the treatment of mild to moderate atrophic acne scarmild to moderate rolling and shallow boxcar acne scars
TCTR20201201003none20
Not yet recruiting
Phase 4
To compare the clinical outcome of topical recombinant human epidermal growth factor and conventional saline dressing in management of diabetic foot ulcers - a randomised controlled trial
CTRI/2024/06/068922Aarupadai veedu medical College and hospital
Not yet recruiting
Phase 3
Effect of topical recombinant human epidermal growth factor on chronic diabetic ulcer compared with conventional saline dressing
CTRI/2024/05/067239Dr A Sneha Daffodil
Completed
Not Applicable
The clinical benefit of topical moisturizers in xerosis patientDiseases of the skin and subcutaneous tissue
KCT0001508Samsung Medical Center80
Completed
Not Applicable
Comparison of topical recombinant human epidermal growth factor versus aloe vera gel in combination with ablative 10,600-nm carbon dioxide fractional laser for the treatment of striae alba: A randomized, double-blind trialStriae albastriae alba&#44recombinant&#45human epidermal growth factor&#44fractional carbon dioxide laser
TCTR20180610001Thammasat University24